In Segment A, individuals will obtain distinctive doses and schedules of oral ABBV-744 tablet to discover safe dosing regimen. More contributors is going to be enrolled at the recognized monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "incorporate-on" therapy. In Section https://abbv-744-in-the-treatment57801.blog2news.com/32551109/the-basic-principles-of-abbv-744-in-acute-myeloid-leukemia-aml